Elliot Marseille
Director of the Collaborative for the Economics of Psychedelics at UC Berkeley
Data updated
Research Footprint
Elliot Marseille appears in 8 tracked papers (2020–2025), most studied alongside MDMA, Psilocybin and Placebo, across Health Economics & Reimbursement, PTSD and Depressive Disorders.
Most-cited paper: The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD (54 citations).
Frequent co-authors: Charles Raison, Michael Mithoefer and Manish Agrawal.
Background & Research
Elliot Marseille, DrPH, MPP, is a health economist whose work sits at the intersection of psychedelic science, public health, and policy. He directs the Collaborative for the Economics of Psychedelics at UC Berkeley and has published widely on the economics of MDMA-assisted psychotherapy, psilocybin-assisted therapy, and group-delivery models. His earlier career focused on HIV/AIDS and global health economics, including work for major public-health and development organizations.
Key Impact
He is a leading health economist in psychedelic research, known for modeling the cost-effectiveness, access, and public-health impact of psilocybin and MDMA-assisted therapies.
Collaboration Network
6 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Elliot Marseille is associated with.
UC Berkeley School of Public Health
UC Berkeley School of Public Health (Berkeley Public Health) is the public health school of the University of California, Berkeley, offering graduate and professional degrees and conducting research and public health practice across areas such as epidemiology, biostatistics, environmental health, and health policy.
View stakeholder →University of California, San Francisco
academicUniversity of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
View stakeholder →